title: Efficacy and Safety of Sofosbuvir Plus Ribavirin Treatment for Patients with Chronic Hepatitis C Genotype 2.
abstract: OBJECTIVE
  The efficacy of sofosbuvir plus ribavirin (RBV) treatment for hepatitis C virus (HCV) genotype 2 focusing on virological response was compared with that of pegylated interferon (peg-IFN) plus RBV treatment. Safety of the former focusing on the decline in hemoglobin levels was compared with that of the latter and assessed in terms of age and inosine triphosphatase (ITPA).
  
  
  METHODS
  Patients (n = 17) receiving sofosbuvir plus RBV and those (n = 24) receiving peg-IFN plus RBV diagnosed with chronic HCV genotype 2 were enrolled in this study, and the efficacy and safety of both treatments were assessed.
  
  
  RESULTS
  Rapid virological response was attained with sofosbuvir plus RBV treatment compared with peg-IFN plus RBV treatment. All patients under sofosbuvir plus RBV treatment achieved end-of-treatment response compared with 70% who sustained viral response under the peg-IFN plus RBV treatment, with the former demonstrating greater virological response. The decline in hemoglobin levels under the former treatment was greater than that under the latter and in patients over 65 years of age with ITPA gene major.
  
  
  CONCLUSIONS
  Efficacy and safety of sofosbuvir plus RBV treatment were clearly demonstrated compared with those of peg-IFN plus RBV treatment. The decline in hemoglobin levels was not related to the discontinuation of the former treatment, irrespective of age or the effect of the ITPA gene.
authors.forename: Kayo
authors.initials: K
authors.lastname: Sugimoto
authors.forename: Soo Ki
authors.initials: SK
authors.lastname: Kim
authors.forename: Soo Ryang
authors.initials: SR
authors.lastname: Kim
authors.forename: Mana
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Airi
authors.initials: A
authors.lastname: Kato
authors.forename: Eri
authors.initials: E
authors.lastname: Morimoto
authors.forename: Susumu
authors.initials: S
authors.lastname: Imoto
authors.forename: Chi Wan
authors.initials: CW
authors.lastname: Kim
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Kudo
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Yano
authors.forename: Yoshitake
authors.initials: Y
authors.lastname: Hayashi
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage*; D004337:Drug Carriers; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D006454:Hemoglobins / Q000032:analysis; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D011755:Pyrophosphatases / Q000235:genetics; D012254:Ribavirin / Q000008:administration & dosage*; D012449:Safety; D000069474:Sofosbuvir / Q000008:administration & dosage*; D016896:Treatment Outcome; D000097630:Inosine Triphosphatase
chemical_list: D000998:Antiviral Agents; D004337:Drug Carriers; D006454:Hemoglobins; D007372:Interferons; D011092:Polyethylene Glycols; D011755:Pyrophosphatases; D012254:Ribavirin; D000069474:Sofosbuvir; D000097630:Inosine Triphosphatase